Evanoa Bioscience

Executive Summary

Evanoa Bioscience is a private San Diego-based biotechnology company specializing in cell line development for biologics manufacturing. Founded in 2019, the company focuses on enabling efficient production of therapeutic proteins, antibodies, and other biologics. In March 2023, Evanoa entered into a licensing agreement with Aldevron, a global leader in plasmid DNA, RNA, and protein production, granting rights to two E. coli strains for plasmid manufacturing. This partnership underscores Evanoa's strategy to collaborate with contract development and manufacturing organizations (CDMOs) to scale its proprietary cell line technology. While the company operates in the oncology and small molecule categories, its core platform supports broader biologics applications. Evanoa remains in early stages with no disclosed funding rounds or clinical pipeline, but its cell line optimization technology could address critical bottlenecks in biologic drug manufacturing, such as yield improvements and stable expression. The company's success hinges on securing additional partnerships and advancing its platform toward commercialization.

Upcoming Catalysts (preview)

• Q3 2026New licensing agreement for cell line platforms40% success
• TBDExpansion into gene therapy or mRNA manufacturing applications30% success
• Q2 2026Series A funding round announcement45% success